TITLE

Once-Weekly Fluoxetine

AUTHOR(S)
Wagstaff, A.J.; Goa, K.L.
PUB. DATE
December 2001
SOURCE
Drugs;Dec2001, Vol. 61 Issue 15, p2221
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
â–´ The relatively long half-life of the selective serotonin reuptake inhibitor fluoxetine has allowed the development of a delayed-release (enteric-coated) formulation containing 90mg fluoxetine per capsule for once-weekly oral administration. â–´ The cumulative relapse rate in patients switched to once-weekly fluoxetine 90mg for 25 weeks (after responding to 13 weeks of fluoxetine 20 mg/day) was similar to that in patients continuing to receive fluoxetine 20 mg/day and significantly lower than seen in patients switched to placebo. â–´ The efficacy of the once-weekly formulation was also similar to that of the daily formulation in other assessment parameters (modified 17-item Hamilton Rating Scale for Depression, Clinical Global Impressions - Severity of Illness Scale). â–´ Patient compliance (measured using an electronically monitored tablet bottle) was maintained at 87.5% in evaluable patients receiving once-weekly fluoxetine 90mg for 12 weeks from a baseline of 85.4% after responding to 4 weeks of fluoxetine 20 mg/day; in contrast, compliance declined significantly (from 87.3% at baseline to 79.4%; p < 0.001) in patients continuing to receive 20 mg/day for 12 weeks. â–´ Once-weekly fluoxetine is well tolerated, with a tolerability profile similar to that of the immediate-release formulation.
ACCESSION #
5692975

 

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics